关键信息
-
基因名
CLEC10A
- 应用
-
别名
CLEC10A；CLECSF13；CLECSF14；HML；C-type lectin domain family 10 member A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8IUN9
-
表达区间
61-316aa
-
氨基酸序列
QNSKFQRDLVTLRTDFSNFTSNTVAEIQALTSQGSSLEETIASLKAEVEG FKQERQAGVSELQEHTTQKAHLGHCPHCPSVCVPVHSEMLLRVQQLVQDL KKLTCQVATLNNNASTEGTCCPVNWVEHQDSCYWFSHSGMSWAEAEKYCQ LKNAHLVVINSREEQNFVQKYLGSAYTWMGLSDPEGAWKWVDGTDYATGF QNWKPGQPDDWQGHGLGGGEDCAHFHPDGRWNDDVCQRPYHWVCEAGLGQ TSQESHVDHHHHHH
-
分子量
30 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CLEC10A, also known as the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN), is a C-type lectin receptor primarily expressed on dendritic cells and macrophages. This receptor plays a critical role in the immune system, particularly in the recognition of glycoproteins on pathogens, facilitating their uptake and subsequent presentation to T cells. The study of CLEC10A recombinant protein has garnered significant attention due to its potential applications in both vaccine development and immunotherapy. Research has demonstrated that CLEC10A can enhance the immune response against various infections, including viral and fungal pathogens, by promoting efficient antigen capture and activation of immune cells. Furthermore, its ability to modulate immune responses opens avenues for therapeutic interventions in autoimmune diseases and cancer. Advances in recombinant DNA technology have enabled the production of CLEC10A as a functional protein, allowing scientists to investigate its structure-function relationship and interactions with ligands, as well as its pharmacological potential. Understanding the biology and mechanisms of CLEC10A could lead to innovative strategies for harnessing the immune system to combat diseases effectively.
